Tampa Bay Total Wellness Anti Aging Med Spa
- Shockwave Therapy
- IV Therapy
- Arthritis Treatment
- Peptide Therapy
- Red Light Therapy
Tampa, FL
Tampa's stem-cell market sits between Tampa General, Moffitt, and USF Health referral gravity and a cash-pay strip that runs South Tampa and Hyde Park suites, Westshore offices, Channelside shops, and St. Pete spillover that still filters under the Tampa Directory. Same "stem cell" label can mean same-day bone marrow or adipose product, an allogeneic cord marketing pitch, or an investigational protocol. Those are not interchangeable.
This hub lists clinics that appear in our Directory for Tampa and stem-cell therapy. Inclusion is not an endorsement, and listing order is not a paid ranking. Regenerated.com is free for patients. Organic relevance and published evidence signals are separate from any labeled Featured or Sponsored placement. Verified badges, when present, reflect credential checks (not spend).
When you evaluate Tampa options, ask what tissue or cell source is used, whether the product is same-day autologous or allogeneic, who performs the procedure, what outcomes they track, how adverse events are handled, and whether marketing language matches FDA product category (Section 361 vs products that need IND or BLA pathways). Academic and cancer-center gravity around Moffitt and TGH does not automatically clean up private-clinic claims in South Tampa or along Westshore.
Prefer clinicians who can explain risks in plain language, document informed consent, and tie claims to published evidence grades rather than before/after grids. We omit invented city price averages here. Use national stem-cell Guides for mechanism literacy, then return here for Tampa listings.
Before you trust badges or counts on this page, read How to read a Regenerated city hub and Featured vs Verified vs organic. Then return here for local listings.
Regulatory context
Florida cellular therapy providers are governed by 21 CFR Part 1271. Section 361 applies to minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 applies to products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND or BLA. Most stem cell, stromal vascular fraction, exosome, umbilical cord blood derived, and culture-expanded mesenchymal cell therapies marketed in Florida for orthopedic, neurologic, autoimmune, and longevity indications fall under Section 351 and lack FDA approval. Florida is a high-volume market, which has translated into elevated federal scrutiny.
Florida has been a primary target of FDA enforcement. In US v US Stem Cell Inc (2019), a federal court in Florida granted a permanent injunction against a Sunrise-based clinic for marketing unapproved stem cell products derived from adipose tissue. The Eleventh Circuit upheld the injunction in 2021. The FDA has issued multiple warning letters to Florida clinics offering exosome and umbilical cord-derived therapies. The Florida Department of Health and the Boards of Medicine and Osteopathic Medicine have disciplined physicians for unprofessional conduct tied to misleading regenerative medicine marketing. The Florida Attorney General has pursued deceptive trade practice claims under FDUTPA against stem cell clinics.
Available here
Nationwide
Stem Cell Therapy clinics across the US